



**HAL**  
open science

## Is oxygen a key factor in the lipodystrophy phenotype?

Christel Gentil, Sébastien Le Jan, Josette Philippe, Jacques Leibowitch,  
Pierre Sonigo, Stéphane Germain, France Piétri-Rouxel

### ► To cite this version:

Christel Gentil, Sébastien Le Jan, Josette Philippe, Jacques Leibowitch, Pierre Sonigo, et al.. Is oxygen a key factor in the lipodystrophy phenotype?. *Lipids Health Dis*, 2006, 5, pp.27. 10.1186/1476-511X-5-27. inserm-00122143

**HAL Id: inserm-00122143**

**<https://inserm.hal.science/inserm-00122143v1>**

Submitted on 27 Dec 2006

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Research

Open Access

## Is oxygen a key factor in the lipodystrophy phenotype?

Christel Gentil<sup>1,2</sup>, Sébastien Le Jan<sup>3</sup>, Josette Philippe<sup>3</sup>, Jacques Leibowitch<sup>4</sup>,  
Pierre Sonigo<sup>1</sup>, Stéphane Germain<sup>3,5</sup> and France Piétri-Rouxel\*<sup>1,2</sup>

Address: <sup>1</sup>Institut Cochin UMR 8104 Inserm U567 Université René Descartes 22 rue Méchain, 75014 Paris, France, <sup>2</sup>GENETHON, CNRS UMR8115, 1 bis rue de l'Internationale, 91002 Evry, France, <sup>3</sup>INSERM U36-Collège de France- 11, place M. Berthelot-75005 Paris, France, <sup>4</sup>Unité d'Immuno-Virologie, Hôpital Raymond Poincaré, 92380 Garches, France and <sup>5</sup>Service d'hématologie biologique A, AP-HP, Hôpital Européen Georges Pompidou, Paris, France

Email: Christel Gentil - gentil@genethon.fr; Sébastien Le Jan - sebastien.le-jan@college-de-france.fr; Josette Philippe - josette.philippe@college-de-france.fr; Jacques Leibowitch - jacques.leibowitch@rpc.ap-hop-paris.fr; Pierre Sonigo - sonigo@cochin.inserm.fr; Stéphane Germain - stephane.germain@college-de-france.fr; France Piétri-Rouxel\* - pietri@genethon.fr

\* Corresponding author

Published: 18 October 2006

Received: 23 June 2006

*Lipids in Health and Disease* 2006, **5**:27 doi:10.1186/1476-511X-5-27

Accepted: 18 October 2006

This article is available from: <http://www.lipidworld.com/content/5/1/27>

© 2006 Gentil et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** The lipodystrophic syndrome (LD) is a disorder resulting from selective damage of adipose tissue by antiretroviral drugs included in therapy controlling human-immunodeficiency-virus-1. In the therapy cocktail the nucleoside reverse transcriptase inhibitors (NRTI) contribute to the development of this syndrome. Cellular target of NRTI was identified as the mitochondrial polymerase-gamma and their toxicity described as a mitochondrial DNA (mtDNA) depletion resulting in a mitochondrial cytopathy and involved in fat redistribution. No mechanisms offer explanation whatsoever for the lipo-atrophic and lipo-hypertrophic phenotype of LD. To understand the occurrence we proposed that the pO<sub>2</sub> (oxygen partial pressure) could be a key factor in the development of the LD. For the first time, we report here differential effects of NRTIs on human adipose cells depending on pO<sub>2</sub> conditions.

**Results and discussion:** We showed that the hypoxia conditions could alter adipogenesis process by modifying expression of adipocyte makers as leptin and the peroxisome proliferator-activated receptor PPARgamma and inhibiting triglyceride (TG) accumulation in adipocytes. Toxicity of NRTI followed on adipose cells in culture under normoxia versus hypoxia conditions showed, differential effects of drugs on mtDNA of these cells depending on pO<sub>2</sub> conditions. Moreover, NRTI-treated adipocytes were refractory to the inhibition of adipogenesis under hypoxia. Finally, our hypothesis that variations of pO<sub>2</sub> could exist between adipose tissue from anatomical origins was supported by staining of the hypoxic-induced angiopoietin ANGPTL4 depended on the location of fat.

**Conclusion:** Toxicity of NRTIs have been shown to be opposite on human adipose cells depending on the oxygen availability. These data suggest that the LD phenotype may be a differential consequence of NRTI effects, depending on the metabolic status of the targeted adipose tissues and provide new insights into the opposite effects of antiretroviral treatment, as observed for the lipo-atrophic and lipo-hypertrophic phenotype characteristic of LD.

## Background

Lipodystrophic syndrome (LD) is a disorder resulting from selective damage to adipose tissue by antiretroviral drugs used to control HIV infection. LD first emerged at about the same time as viral protease inhibitors (PIs) were first introduced but it is currently thought that both PIs and a second class of anti-viral drugs – nucleoside reverse transcriptase inhibitors (NRTI) – contribute to the development of this syndrome [1]. Studies *in vitro* have shown that PIs affect fat-cell differentiation and the expression of adipose markers in the subcutaneous fat tissue of patients with LD [2]. The cellular target of NRTI was identified as the mitochondrial polymerase- $\gamma$  involved in the mitochondrial DNA (mtDNA) repair and replication. NRTI toxicity seems to involve mostly massive mtDNA depletion, resulting in a mitochondrial cytopathy; it has also recently been implicated in fat redistribution syndrome (see for review [3-5]). In human primary preadipocytes, NRTIs have been described to induce a strong mtDNA and to affect the function of mitochondrial respiratory chain [6]. Recent studies on 3T3-F442A preadipocytes exposed to stavudine (d4T), zidovudine (AZT), ddC or didanosine (ddl) showed that d4T, ZDV and ddC decreased adipocyte mtDNA while ddl had no effects [7]. Furthermore, *in vivo* mtDNA depletion in adipose cells has been shown to be associated with a dysfunction of the mitochondrial oxidative phosphorylation chain [8]. However, NRTIs were also described to decrease transcription of mtRNA in absence of depletion of mtDNA [9]. Moreover, they were shown to alter expression of both mitochondrial and lipid metabolism genes. These data suggest that NRTIs may also cause mitochondrial dysfunction by other means than through inhibition of DNA polymerase gamma and in this context, disruption of expression of lipid metabolism genes offers an explanation for NRTI-induced lipoatrophy [9].

Adipose tissue, which was once thought to function primarily as a passive depot for the storage of excess lipid, is now understood to play a much more active role in metabolic regulation, secreting numerous proteins, including leptin, resistin, adiponectin, acylation-stimulating protein, tumor necrosis factor-alpha and interleukin-6 (IL-6), in response to various stimuli. These secreted proteins have pleiotropic effects; their involvement in glucose and fat metabolism may affect insulin resistance. Based on their anatomical location, subcutaneous and visceral adipose tissues may be involved in controlling the efficiency of lipolysis or the metabolic disturbances associated with visceral obesity, including glucose intolerance, hyperinsulinemia, insulin resistance, hypertension and dyslipoproteinemia (see for review[10]). Furthermore, levels of adipokines and of vascular endothelial growth factor (VEGF), IL-6 and the plasminogen-activator inhibitor-1 (PAI-1) released have been shown to be higher in visceral than in abdominal subcutaneous tissue [11]. All of these

are hypoxia target genes and further suggesting that hypoxia might regulate adipogenesis. Adipocyte differentiation *in vitro* is inhibited under hypoxic conditions, indicating that oxygen is an important physiological regulator of adipogenesis [12]. Moreover, angiopoietin-like 4 protein (ANGPTL4), also known as PPAR $\gamma$  angiopoietin-related (PGAR) or fasting-induced adipose factor (FIAF), is a protein that has been reported to be expressed in adipose tissue and placenta and associated with adipose differentiation [13]. The *angptl4* gene was recently demonstrated to display hypoxia-induced expression in various cell types and to modulate angiogenesis in tumor and ischemic tissues, suggesting that this protein could provide a link between metabolic disorders and the regulation of angiogenesis by hypoxia [14,15].

Adipose tissue has been shown to have unique properties in plasticity, a capacity for vascular remodeling, and susceptibility to angiogenesis inhibitors. These characteristics result from the maintenance of immature adipose vessels, which facilitates vascular/tissue remodeling [16]. In an obese mouse model, angiogenesis inhibitors designed to inhibit tumor growth were shown to reduce adipose tissue mass by cutting off the blood supply [17]. The reciprocal regulation of adipogenesis and angiogenesis was suggested by blocking VEGF signaling, which inhibited adipose tissue formation *in vivo* [18].

The redistribution of body fat in patients with LD entails the visceral accumulation of white adipose tissue and subcutaneous fat wasting. It remains unclear why adipose tissue is affected differently in different regions of the body, as in the lipo-atrophic and lipo-hypertrophic phenotype characteristic of LD. Various hypothesis were proposed to explain abnormal body-fat distribution in HIV-1-associated adipose redistribution syndrome. The neurological hypothesis was based on neuroanatomical studies showing autonomic control of white adipose tissue by both the sympathetic and parasympathetic branch, with separate sets of autonomic neurons innervating either the subcutaneous or the visceral fat compartment. Fliers et al proposed that adipose redistribution syndrome is mediated by effects of antiretroviral treatment on the central nervous system and could indicate a change in autonomic balance resulting in redistribution of adipose tissue [19]. An immunological hypothesis was also brought by the data reporting that fat accumulation in the breast in women on antiretroviral treatment was associated to a particular immunologic profile characterized by good T-helper activity and normalization of macrophage-derived cytokines (IL-12, TNF-(alpha)) [20].

In order to investigate whatsoever O<sub>2</sub> might have a role in the LD phenotype, the effects of hypoxia on adipogenesis were investigated. We demonstrated that hypoxia modi-

fied the pattern of production of crucial adipocyte factors, including PPAR $\gamma$ , leptin, the angiogenic factors VEGF and ANGPTL4. In addition, levels of the transcription factor HIF-1 $\alpha$  were stable in hypoxic preadipocyte nuclei. Moreover, triglyceride (TG) accumulation in adipocytes was strongly inhibited during adipogenesis following hypoxia. These data are consistent with pO<sub>2</sub> (oxygen partial pressure) variations having an effect on the molecular and metabolic status of adipocytes. We then investigated the toxicity of NRTI in adipose cells under normoxia and hypoxia. We provide here the first demonstration that the effects of NRTI treatment on adipose cells depend on pO<sub>2</sub> in culture conditions. Finally, we tested the hypothesis that pO<sub>2</sub>-adipogenesis-angiogenesis state differs in adipose tissues from different anatomical origins, by studies of hypoxia-induced angiopoietin ANGPTL4 expression in sections of adipose tissue. Staining depended on the location of fat deposits and the results obtained suggested that staining was associated with hypoxic microenvironments, which may be in a different metabolic state, thereby partly accounting for differences in the response to NRTI treatment.

These results provide new insights into the effects of antiretroviral treatment, differently affecting different regions of the body, as observed for the lipo-atrophic and lipo-hypertrophic phenotype characteristic of LD.

## Results

### Effects of hypoxia on adipogenesis

We investigated whether low pO<sub>2</sub> affected adipogenesis by allowing human primary preadipocyte to differentiate in the presence of the standard cocktail of adipogenic hormones (+ MIX) under gaseous hypoxia (1% O<sub>2</sub>) or chemical hypoxia (DFO). We then compared TG accumulation with that in normoxia (20% O<sub>2</sub>) (Fig. 1A). Under normoxia, 80 to 90% of preadipocytes differentiated into mature adipocytes loaded with TG droplets, as demonstrated by colorimetric quantification of Red-Oil staining. However, adipocyte differentiation was inhibited when adipogenesis was induced under hypoxia (DFO or 1% O<sub>2</sub>), consistent with previous results for the preadipocyte-like L1 cell line [12].

We investigated the effect of hypoxia on the production of adipocyte factors, mRNA synthesis for the transcription factor PPAR $\gamma$ , and the adipokine leptin in confluent preadipocytes cultured under DFO treatment. We also assessed expression of the pro-angiogenic vascular endothelial growth factor VEGF, which has been reported to be a hypoxia response factor upregulated in rodent adipocyte cell lines treated with drugs mimicking hypoxia [21]. PPAR $\gamma$  cDNA levels decreased (Fig. 1B), despite increases in leptin and VEGF levels, showing that hypoxia


can modulate key markers of adipogenesis and angiogenesis in human preadipocytes.

The cellular response to hypoxia is strongly linked to the stabilization of HIF-1 $\alpha$ , which regulates hypoxia-responsive genes. We investigated HIF-1 $\alpha$  stabilization and leptin protein production in preadipocytes cultured under hypoxia (Fig. 1C). Following the exposure of cells to hypoxia (+DFO), immunofluorescence staining showed, as expected, accumulation of the transcription factor HIF-1 $\alpha$  in the nucleus (a) and of leptin protein in cytoplasmic vesicles (b). Double-staining experiments indicated that leptin was produced mostly in preadipocytes expressing the hypoxic marker HIF-1 $\alpha$  (c). These data strongly suggest that pO<sub>2</sub> variations may affect the molecular and metabolic status of adipose cells.

### Differential effects of NRTI treatment on human adipose cells cultured under different pO<sub>2</sub>

The cellular target of NRTI has been identified as the mitochondrial polymerase  $\gamma$ , and mtDNA depletion has been observed in treated cells. We investigated the dual toxicity of NRTI in fat deposits, taking into account the possible effects of variations of pO<sub>2</sub> on adipogenesis, by assessing the toxicity of NRTI in adipose cells under normoxia and hypoxia (Fig. 2). Quantification of mtDNA (Fig. 2A) revealed that NRTI treatment induced severe mtDNA depletion in preadipocytes maintained in normoxia (20% O<sub>2</sub>). However, no NRTI-induced depletion was observed in preadipocytes cultured in hypoxia (DFO), despite weak decreases in mtDNA content the low pO<sub>2</sub>. We investigated the effect of NRTI on metabolically active adipose cells by quantifying mtDNA levels in mature adipocytes treated with NRTI during differentiation (Fig. 2A). Adipocytes gave similar results to preadipocytes: mtDNA depletion in NRTI-treated cells under normoxia and no significant depletion under hypoxia.

We assessed TG accumulation in mature adipocytes treated with NRTI during differentiation (Fig. 2B). No TG accumulation was detected in preadipocytes, with or without NRTI. Lipid accumulation levels were similar in adipocytes differentiated in normoxia and treated with NRTI and in untreated cells. Differentiation was strongly inhibited under hypoxia (Fig 1A and Fig 2B). Paradoxically, NRTI-treated adipocytes were refractory to the inhibition of adipogenesis under hypoxia, as cells accumulated TG to levels similarly to cells under normoxia. In order to determine whether, in this condition, hypoxia can induce lipid accumulation independently of adipocyte differentiation, expression of the two adipocyte markers, PPAR $\gamma$  and leptin, was evaluated (Fig 2C). Quantitative RT-PCR results showed that NRTIs treatment (black bars) did not modify PPAR $\gamma$  nor leptin gene expression in normoxia compared to control cells (hatched bars). These data also showed



**Figure 1**

**Effects of hypoxia on adipogenesis.** (A) Hypoxia inhibits TG accumulation. Cells were allowed to differentiate for 15 days with differentiation mix (black bars) under normoxia (20%), gaseous hypoxia (1%) or chemical hypoxia (100  $\mu$ M DFO). TG accumulation was quantified by colorimetric determination of Red-Oil staining. Data are presented as optical density at 495 nm ( $OD_{495}$  nm). n = 4, \*\*p < 0.001. (B) Hypoxia modulated adipocyte gene expression. Confluent cells were treated for 24 hours with 100  $\mu$ M DFO (+) grey bars or were not treated (-) white bars. RNA was extracted and expression of the PPAR $\gamma$ , leptin and VEGF genes was followed by quantitative PCR. n = 2, \*\*p < 0.01. (C) Localization of HIF-1 $\alpha$  and leptin protein in hypoxia-stimulated cells. Cells were treated for 24 hours with 100  $\mu$ M DFO (+DFO) or were not treated (-DFO). Proteins were detected with mAB against HIF1- $\alpha$  tagged with a goat anti-mouse IgG coupled to FITC (a) or with mAB against leptin tagged with a goat anti-rabbit IgG coupled to cy3 (b), or a co-staining (c).

that, as described in figure 1B, PPAR $\gamma$  gene expression was

down regulated and *leptin* gene expression was up-regulated in preadipocytes (P) treated by DFO compared with normoxia (20%). However, in the treated adipocytes (DFO, A, NRTI) where hypoxia did not inhibit differentiation since the amount of lipids was maintained (Fig 2B), expression of PPAR $\gamma$  was down regulated and the leptin was up-regulated. These data suggest that, in this condition, hypoxia can induce lipid accumulation independently of adipocyte differentiation marker PPAR $\gamma$ , as previously described by Fink et al [22].

Thus, the effect of NRTI depends on pO<sub>2</sub> conditions. Indeed, mtDNA was severely depleted under normoxia, but not under hypoxia, and NRTI-treated adipose cells were refractory to the inhibitory effects of hypoxia on TG accumulation.

**Differential ANGPTL4 expression was observed in adipose tissue sections, depending on their site of origin in the body**


ANGPTL4 has been identified as an adipocytokine upregulated by fasting, PPAR agonists [13,23,24] and hypoxia [14]. We first investigated whether hypoxia also induced *angptl4* gene expression in human primary adipocyte cultures, as previously shown in endothelial cells. Quantitative PCR performed on total RNA extracted from adipocytes cultured under normoxic or hypoxic conditions showed that *angptl4* gene expression was 6.5 fold increased by hypoxia compared to control ( $p < 0.001$ ) (Fig. 3A). Moreover, potential effect of NRTIs on *angptl4* gene expression was evaluated and no modification could be exhibited by NRTI treatment, neither in normoxic nor in hypoxic conditions (Fig. 3A).

We therefore used ANGPTL4 expression *in vivo* as a surrogate marker for investigating the physiological relevance of differential pO<sub>2</sub>-adipogenesis-angiogenesis states according to the location of the adipose tissue. We analyzed ANGPTL4 expression by immunohistochemical staining of adipose tissue sections (Fig. 3B) from subcutaneous (a), omental (b), and mammary fat deposits (c). We also studied sections of proliferating adipose tissue from pathological areas around adrenal medulla tumor pheochromocytoma (d) and from the lipo-hypertrophic zone of lipodystrophic patients treated for HIV infection (e). ANGPTL4 protein was present in the cytoplasm of mature adipocytes in visceral adipose tissue, but no labeling was detected in the subcutaneous and mammary fat pads (Table 1). However, the adipose tissue associated with pathological conditions, around pheochromocytoma and in the lipo-hypertrophic zone of HIV patients, was stained. Staining for leptin, a well-known adipocyte marker, was detected in all adipose tissue sections examined (Fig. 3B). Finally, immunohistochemical studies showed that the differential expression of ANGPTL4 depended on the anatomical origin of the adipose tissue,

suggesting that the metabolic status of adipose tissue may indeed depend on its location within the body.


**Discussion**

Previous studies have provided evidence to suggest that pO<sub>2</sub> variations and angiogenesis modulate adipogenesis [16,17,25,26] indeed the high level of plasticity of adipose tissue is regulated via the vasculature [27]. In the present study, we found that O<sub>2</sub> availability affected the expression of genes encoding adipokines, such as leptin, which has been shown to induce angiogenesis and to influence angiogenic factors [28-30]. We found that the production of leptin protein was associated with stabilization of the transcription factor HIF-1 $\alpha$  (Fig. 1C), confirming the results of previous studies showing that leptin is encoded by a hypoxia-inducible gene [31]. TG accumulation was inhibited in preadipocytes maintained in hypoxia during adipogenesis, consistent with data obtained in a rodent preadipocyte cell line [12]. Yun *et al.* suggested that adipogenesis was regulated via the inhibition of PPAR $\gamma$  2 gene expression by the product of the HIF-1-regulated gene DEC1/Stra13 [12]. Furthermore, The effects of adipose tissue metabolism, which depends on O<sub>2</sub> availability, on response to NRTI treatment has been proposed as a model for investigating the differential effects of anti-retroviral drugs [6]. In the present work, we tested the hypothesis that the effects of NRTI depend on pO<sub>2</sub>. We first demonstrated that the effects of NRTI on mtDNA content were O<sub>2</sub>-dependent (Fig. 2A and 2B), suggesting that mitochondria, which are highly active in normoxic conditions, need to replicate their mtDNA in such conditions, rendering them more sensitive to NRTI polymerase- $\gamma$  inhibition than cells maintained in hypoxia. Surprisingly, NRTI-treated cells were refractory to the hypoxia-mediated inhibition of adipogenesis (Fig. 3C), suggesting that the consequences of hypoxia may be profoundly modified by NRTI treatment. In LD patients, NRTI-associated mtDNA depletion in adipocytes has been reported to affect the function of mitochondrial respiratory proteins [6,8]. Under hypoxia, mitochondrial respiration inhibitors have been shown to induce the redistribution of intracellular O<sub>2</sub> [32]. Hagen *et al.* used the renilla luciferase system to determine intracellular O<sub>2</sub> concentrations. They showed that O<sub>2</sub> was redistributed to cells not registering hypoxia, thereby preventing the stabilization of HIF-1 $\alpha$ . If inhibition of the mitochondrial respiratory chain restores intracellular O<sub>2</sub> availability then, given that lipogenesis requires high pO<sub>2</sub> levels, as shown in this study, NRTI-treated cells may not register hypoxia and thus accumulate TG similarly to cells in normoxic conditions. O<sub>2</sub> is a major regulator of the glycolytic pathway and of the mitochondrial respiratory chain. In particular, mitochondrial oxidative phosphorylation generates a chemo-osmotic gradient favoring the entry of pyruvate into the tricarboxylic acid (TCA) cycle to



**Figure 2**

**Differential effects of NRTI treatment on human adipose cells cultured under different pO<sub>2</sub>.** (A) Effects of NRTI treatment on mtDNA contents. Cells were cultured for 10 days as preadipocytes (P) or with Mix medium (A) under normoxia (20%) or in the presence of 100 μM DFO (DFO) plus a cocktail of 10 μM AZT and ddC (NRTI, black bars), or in the presence of 100 μM DFO but without the NRTI cocktail (C, hatched bars). Cell mtDNA was quantified and expressed per million cells (mtDNA/10<sup>6</sup> cells). n = 3, \*\* p < 0.001. (B) Effects of NRTI treatment on TG accumulation. Cells were cultured in the same experimental conditions than in panel (A) and TG were quantified and data were normalized with respect to the control value obtained in adipocytes allowed to differentiate under normoxia condition (20% A, hatched bar, OD<sub>495</sub> nm = 0.25). n = 3, \*\* p < 0.001. (C) Effects of NRTI treatment on adipocyte marker expression. Cells were cultured in the same experimental conditions than in panel (A), RNA was extracted and expression of the PPAR $\gamma$ , leptin genes was followed by quantitative PCR. n = 2.



**Figure 3**  
**ANGPTL4 expression study of adipose tissue sections.** (A) *Angptl4* is a target of hypoxia in human adipose cells. Quantitative PCR analysis of ANGPTL4 mRNA in adipocytes (white bar), cultured for 24 hours in chemical DFO hypoxic condition (grey bar). n = 2, p < 0.001. (B) Differential ANGPTL4 and leptin expression in adipose tissue sections depending on the anatomical origin of the adipose tissue. We assessed ANGPTL4 (left panel) and leptin (right panel) levels by immunostaining subcutaneous (a), omental (b), and mammary (c) fat deposits and adipose tissues around a pheochromocytoma (d) and from the lipo-hypertrophic zone of lipodystrophic patients treated for HIV (e). Immunostaining with an isotypic control was carried out for each sample tested: a', b', c', d' and e'.



**Table 1: In vivo Angptl4 expression in adipose tissues**

origin of adipose tissues	n	expression levels
Abdo s/s cut	9	-
Abdo omental	3	+++
Mammary	10	-
Pheochromocytoma	3	+++
Lipo-hypertrophic zone of LD	3	+++

Adipose tissue immunostaining was performed on subcutaneous abdominal (Abdo s/s cut), intraperitoneal (Abdo omental) or mammary adipose tissues, on fat depots around area of pheochromocytoma tumor (Pheochromocytoma) and lipo-hypertrophic zone of lipodystrophic treated HIV-patients. (n) indicates the number of different samples tested. Expression levels are indicated by + signs.

generate citrate, a crucial step for fatty acid synthesis. Under hypoxia, anaerobic glycolysis generates pyruvate that does not enter the TCA cycle. This molecule is instead transformed into lactic acid, decreasing the amount of citrate available for fatty acid synthesis. Succinate accumulation has been reported to link this mitochondrial TCA intermediate to the cytosolic inhibition of HIF-1 $\alpha$  prolyl hydroxylase, leading to the stabilization and activation of HIF-1 $\alpha$  [33]. Metabolic regulation mechanisms of this type add an additional level of complexity to the pattern of HIF-1 $\alpha$ -regulated gene expression.

LD syndrome highlights regional differences in adipocyte biology. Studying the heterogeneity in function and responsiveness of fat from visceral and subcutaneous deposits could provide new insight in pathological process. Indeed, differences in insulin action, lipolytic or antilipolytic responses and cytokine production have shown that the metabolic status of adipose tissues may depend on their location in the body (see for review [10]). However, little is known about quantitative or qualitative differences in vascularization [26]. Endothelial progenitor cells have been detected in the stroma vascular fraction isolated from adipose tissue, providing further evidence for a link vasculogenesis, angiogenesis and adipogenesis [34]. However, no data are available regarding the microcirculation and pO<sub>2</sub>. Nevertheless, the presence of the angiogenic factor VEGF, which is produced and secreted in rat adipose tissue, has been shown to be dependent on the fat deposit considered, being highest in omental deposits [35]. In obese patients, visceral fat deposits have been shown to release more VEGF and IL-6 than abdominal subcutaneous tissue [11]. The recently described hypoxia-induced adipokine ANGPTL4 was found to be a good candidate molecule for studies of the metabolic states of adipose cells according to pO<sub>2</sub> microenvironment. ANGPTL4 was strongly expressed in the peri-adrenal adipose tissue around a pheochromocytoma and in lipohypertrophic (table 1), in which adipose fat mass

increases, suggesting that through secretion of angiogenesis modulators adipocytes may have autocrine effects on their own growth. In non-pathological tissues, only visceral adipose tissue was found to express ANGPTL4. If the expression of this protein was associated with a hypoxic microenvironment, then adipogenesis levels would be expected to be low in that zone but NRTI treatment would modify the adipogenic metabolism of cells that would become refractory to hypoxia.

Our study shows that (i) Hypoxia may modify the adipogenic metabolism of primary human adipose cells; (ii) Toxicity of NRTI depends of oxygen environment of adipose cells; and (iii) The differential expression of ANGPTL4 suggests modulation of pO<sub>2</sub> environment according to the anatomical origin of the adipose tissue. Thus, our data suggest that the LD phenotype may be a differential consequence of NRTI effects, depending on the metabolic status of the targeted adipose tissues. However, more extensive investigations on the relationships between hypoxia, angiogenesis and adipogenesis are required to elucidate the physiopathology of adipose tissue in LD or in obesity.

## Methods

### Cell culture, drug treatments and quantification of lipid accumulation

Fragments of waste adipose tissues collected from subcutaneous abdominal wall were obtained during cosmetic surgery on healthy subjects. For studies using adipose tissue from HIV-infected patients the samples were obtained from waste abdominal fat in lipohypertrophic zone during repair surgery. The tissue sample was cut into small pieces and processed as previously described [36]. Preadipocytes from the stromal vascular fraction were cultured in medium (1:1 mixture of Ham's F12/Dulbecco's Modified Eagle's Medium (Invitrogen) supplemented with 20 mM HEPES, 10% decomplemented fetal calf serum, FCS, and antibiotics). Confluent cells were allowed to differentiate for 12 to 15 days. Their differentiation was favored by adding a mixture (Mix) containing 8.5 nM insulin (Sigma Aldrich), 1  $\mu$ M dexamethasone (Sigma Aldrich), 250 nM isobutyl methyl xanthine IBMX (Sigma Aldrich) and 1  $\mu$ M pioglitazone (generously provided by V. Zilberfarb) to the medium. NRTI treatment was carried out by a nucleoside analog cocktail consisting of 10  $\mu$ M azidothymidine (AZT) (Sigma Aldrich) and 10  $\mu$ M 2'3' diideoxycytosine (ddC) (generously provided by Dr J. Leibowitch) to the cell culture medium every two days. Hypoxia was achieved by culturing cells in an atmosphere containing 1% O<sub>2</sub> (incubator IG750 Jouan) or in the presence of 100  $\mu$ M deferoxamine mesylate (DFO) (Sigma Aldrich). Lipid accumulation was quantified by staining triglycerides with Oil Red O solution (Sigma Aldrich) and TG were quantified as previously described [37].

**Immunocytochemical and immunohistochemical analysis**

Human preadipocytes were plated on glass slides. HIF-1 $\alpha$  and leptin levels were assessed in cells fixed in 4% paraformaldehyde and quenched in 0.2 M NH<sub>4</sub>Cl. Cells were blocked by incubation with 2% bovine serum albumin and 2% SVF in PBS. They were then incubated for 90 minutes at room temperature with a mAb against HIF-1 $\alpha$  (1:50, R&D Systems) or with a mAb against leptin (1:20, Santa Cruz Biotechnology). Antibody binding was detected by incubation with a goat anti-mouse IgG coupled to FITC (1:100 Beckman Coulter) for HIF-1 $\alpha$ , or a goat anti-rabbit IgG coupled to cy3 (1/250, Amersham Pharmacia Biotech) for leptin. The samples were then examined under an epifluorescence microscope (Axio-phot; Zeiss, Oberkochen, Germany).

Human adipose tissue was fixed overnight in 4% paraformaldehyde in PBS at 4 °C; samples were then dehydrated and embedded in paraffin. Sections (3  $\mu$ m) were cut and processed for immunohistochemistry. Paraffin was removed from the sections, which were then treated with peroblok (ZYMED) and incubated with the leptin-specific antibody described above or with the antibody directed against human ANGPTL4 used and validated by Le Jan *et al* [14]. Sections were then incubated with the specific substrate, using the Zymed kit method according to the manufacturer's instructions (Sigma Aldrich). Sections were dehydrated and viewed under a light microscope (Leica).

**Mitochondrial DNA quantification**

Total DNA (nuclear and mitochondrial) from drug-treated and untreated cells was collected in 100  $\mu$ l elution buffer with the QIAamp DNA Blood Mini Kit (QIAGEN), and mtDNA was quantified by real-time PCR. For each DNA extract, the nuclear gene encoding  $\beta$ -globin and the mitochondrial 12S RNA gene were quantified separately, as previously described [38]. Data were analyzed using LightCycler Software version 3.5.  $\beta$ -globin genes were quantified using the LightCycler-Control Kit DNA (Roche).

**Gene expression studies**

For RT-PCR, the first-strand cDNA was synthesized from 1  $\mu$ g of total RNA, using the Moloney murine leukemia virus reverse transcriptase (Superscript II Plus, Invitrogen), according to the manufacturer's protocol. Controls without reverse transcriptase were performed to exclude DNA contamination. We amplified 100 ng of first-strand cDNA with 1 U *Taq* polymerase (Invitrogen) and 250  $\mu$ M gene-specific sense- and antisense-primers (Invitrogen) in a thermocycler (GeneAmp PCR System 9600, Perkin-Elmer Cetus). We amplified the cDNAs for PPAR $\gamma$  with the primers sense: 5'TTTCACATATGGAGTTCATGCTTGTG3', antisense: 5'TTTTTGTGGATCCGACAGTTAAGA3'; for lep-

tin sense : 5'GCCTTCCAGAAACGTGATCC3', antisense : 5'GGCCAGCACGTGAAGAAGAT3'; VEGF sense : 5'TACCTCCACCATGCCAAGTG3', antisense :5'GATGATTCTGCCCTCCTCCTT3'; for ANGPTL4 sense 5'CGTACCCTTCTCCACTTGGG and antisense 5'GCTCTTGGCGCAGTTCTTG, for PO (sense 5'GGCGACCTGGAAGTCAACT and antisense 5'CCATCAGCACCACAGCCTTC3'. cDNA levels were quantified by real-time quantitative PCR performed on Taqman AbiPrism 7700 Sequence Detector using Syber-Green JumpStart TaqReadyMix kit. Analysis of the target messages (ANGPTL4, PPAR $\gamma$ , Leptin, VEGF, PO) quantification was done by measuring Ct and by using a standard curve to determine the starting target message quantity as described in [39]. Briefly, the standard curve was constructed with four-fold serial dilutions of cDNA obtained from the differentiated adipocytes, known to express strongly the PPAR $\gamma$ , leptin and VEGF gene. To ANGPTL4, we used preadipocytes treated with DFO. We therefore quantified in all samples transcripts of the PO gene encoding human acidic ribosomal phosphoprotein PO ubiquitously expressed as the endogenous RNA control and each sample was normalized on the basis of its PO content.

**Statistical analysis**

Data were presented as means  $\pm$  standard deviation (SD) and analyzed by both one-way and two-way ANOVA procedures. A *p* value < 0.05 was considered statistically significant, \*\* indicated *p* < 0.001.

**Abbreviations**

LD, lipodystrophic syndrome; NRTI, nucleoside reverse transcriptase inhibitors; mtDNA, mitochondrial DNA; PPAR $\gamma$ , peroxisome proliferator-activated receptor gamma; TG, triglyceride; pO<sub>2</sub>, oxygen partial pressure ; VEGF, vascular endothelial growth factor; ANGPTL4, Angiopoietin-like 4 protein; AZT, azidothymidine; ddC, 2'3' diolseoxycytosine; DFO, deferoxamine mesylate.

**Authors' contributions**

CG, carried out cell culture, drug treatments, quantification of lipid accumulation, mitochondrial DNA quantification and immunocytochemical experiments. SLJ, carried out gene expression studies and Immunocytochemical analysis.

JP, carried out immunohistochemical experiments.

JL, participated in the design of the study, participated in its design and coordination and helped to draft the manuscript.

PS, participated in the design of the study, participated in its design and helped to draft the manuscript.

SG carried out the molecular genetic studies, participated in coordination and helped to draft the manuscript

FP-R conceived of the study and its design, coordinated work and drafted the manuscript

All authors read and approved the final manuscript.

## Acknowledgements

This work was supported by the *Ensemble Contre le Sida-SIDACTION* Foundation. We thank Dr Richard Léandri for providing waste fat specimens and Géraldine Ducros for excellent technical assistance. SG belongs to the European Vascular Genomics Network, a Network of Excellence supported by the European Community's Sixth Framework Programme for Research Priority 1 "Life sciences, genomics and biotechnology for health" (Contract N° LSHM-CT-2003-503254). SG is supported by grants from *la Fondation de France* and Cancerpole-PACA ACI 2004.

## References

- van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA: **Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.** *Aids* 2001, **15(7)**:847-855.
- Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Lubinski J, Laville M, Maaachi M, Girard PM, et al.: **Association between altered expression of adipogenic factor SREBP1 in lipotrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance.** *Lancet* 2002, **359(9311)**:1026-1031.
- Lewis W: **Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions.** *Antiviral Res* 2003, **58(3)**:189-197.
- Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B, Mallal S: **Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.** *Aids* 2003, **17(9)**:1329-1338.
- Nolan D, Mallal S: **The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.** *J HIV Ther* 2004, **9(2)**:34-40.
- Petit C, Pietri-Rouxel F, Lesne A, Leste-Lasserre T, Mathez D, Naviaux RK, Sonigo P, Bouillaud F, Leibowitch J: **Oxygen consumption by cultured human cells is impaired by a nucleoside analogue cocktail that inhibits mitochondrial DNA synthesis.** *Mitochondrion* 2005, **5(3)**:154-161.
- Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, Caron M: **Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions.** *Antivir Ther* 2006, **11(1)**:25-34.
- Hammond E, Nolan D, James I, Metcalf C, Mallal S: **Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy.** *Aids* 2004, **18(5)**:815-817.
- Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, Chisholm D, Samaras K, Emery S, Kelleher A, et al.: **In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.** *J Infect Dis* 2005, **191(10)**:1686-1696.
- Lafontan M, Berlan M: **Do regional differences in adipocyte biology provide new pathophysiological insights?** *Trends Pharmacol Sci* 2003, **24(6)**:276-283.
- Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW: **Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans.** *Endocrinology* 2004, **145(5)**:2273-2282.
- Yun Z, Maecker HL, Johnson RS, Giaccia AJ: **Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stral3: a mechanism for regulation of adipogenesis by hypoxia.** *Dev Cell* 2002, **2(3)**:331-341.
- Yoon JC, Chickering TW, Rosen ED, Dussault B, Qin Y, Soukas A, Friedman JM, Holmes WE, Spiegelman BM: **Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation.** *Mol Cell Biol* 2000, **20(14)**:5343-5349.
- Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J, Philippe J, Sibony M, Gasc JM, Corvol P, et al.: **Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma.** *Am J Pathol* 2003, **162(5)**:1521-1528.
- Ito Y, Oike Y, Yasunaga K, Hamada K, Miyata K, Matsumoto S, Sugano S, Tanihara H, Masuho Y, Suda T: **Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4.** *Cancer Res* 2003, **63(20)**:6651-6657.
- Dallabrida SM, Zurakowski D, Shih SC, Smith LE, Folkman J, Moulton KS, Rupnick MA: **Adipose tissue growth and regression are regulated by angiopoietin-1.** *Biochem Biophys Res Commun* 2003, **311(3)**:563-571.
- Liu L, Meydani M: **Angiogenesis inhibitors may regulate adiposity.** *Nutr Rev* 2003, **61(11)**:384-387.
- Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain RK: **Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis.** *Circ Res* 2003, **93(9)**:e88-97.
- Fliers E, Sauerwein HP, Romijn JA, Reiss P, van der Valk M, Kalsbeek A, Kreier F, Buijs RM: **HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy.** *Lancet* 2003, **362(9397)**:1758-1760.
- Galli M, Gervasoni C, Ridolfo AL, Trabattoni D, Santambrogio S, Vaccarezza M, Meroni L, Trifiro G, Moroni M, Norbiato G, et al.: **Cytokine production in women with antiretroviral treatment-associated breast fat accumulation and limb wasting.** *Aids* 2003, **17(Suppl 1)**:S155-161.
- Lolmede K, Durand de Saint Front V, Galitzky J, Lafontan M, Bouloumie A: **Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes.** *Int J Obes Relat Metab Disord* 2003, **27(10)**:1187-1195.
- Fink T, Abildtrup L, Fogd K, Abdallah BM, Kassem M, Ebbesen P, Zachar V: **Induction of adipocyte-like phenotype in human mesenchymal stem cells by hypoxia.** *Stem Cells* 2004, **22(7)**:1346-1355.
- Kersten S, Mandart S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W: **Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene.** *J Biol Chem* 2000, **275(37)**:28488-28493.
- Yoshida K, Shimizugawa T, Ono M, Furukawa H: **Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase.** *J Lipid Res* 2002, **43(11)**:1770-1772.
- Hattori K, Sumi T, Yasui T, Morimura M, Nobeyama H, Okamoto E, Noriyuki M, Honda K, Kiyama H, Ishiko O: **VEGF mRNA in adipocytes increase with rebound weight-gain after diet-restriction.** *Int J Mol Med* 2004, **13(3)**:395-399.
- Hausman GJ, Richardson RL: **Adipose tissue angiogenesis.** *J Anim Sci* 2004, **82(3)**:925-934.
- Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ: **Adipose tissue mass can be regulated through the vasculature.** *Proc Natl Acad Sci U S A* 2002, **99(16)**:10730-10735.
- Bouloumie A, Drexler HC, Lafontan M, Busse R: **Leptin, the product of Ob gene, promotes angiogenesis.** *Circ Res* 1998, **83(10)**:1059-1066.
- Artwohl M, Roden M, Holzenbein T, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM: **Modulation by leptin of proliferation and apoptosis in vascular endothelial cells.** *Int J Obes Relat Metab Disord* 2002, **26(4)**:577-580.

30. Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, Spencer-Hansch C, Graf K, Nurnberg B, Law RE, et al.: **Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands.** *Hypertension* 2002, **40(5)**:748-754.
31. Grosfeld A, Andre J, Hauguel-De Mouzon S, Berra E, Pouyssegur J, Guerre-Millo M: **Hypoxia-inducible factor 1 transactivates the human leptin gene promoter.** *J Biol Chem* 2002, **277(45)**:42953-42957.
32. Hagen T, Taylor CT, Lam F, Moncada S: **Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha.** *Science* 2003, **302(5652)**:1975-1978.
33. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E: **Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase.** *Cancer Cell* 2005, **7(1)**:77-85.
34. Miranville A, Heeschen C, Sengenès C, Curat CA, Busse R, Bouloumie A: **Improvement of postnatal neovascularization by human adipose tissue-derived stem cells.** *Circulation* 2004, **110(3)**:349-355.
35. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, Rosengart TK: **Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis.** *J Surg Res* 1997, **67(2)**:147-154.
36. Hazan U, Romero IA, Canello R, Valente S, Perrin V, Mariot V, Dumonceaux J, Gerhardt CC, Strosberg AD, Couraud PO, et al.: **Human adipose cells express CD4, CXCR4, and CCR5 [corrected] receptors: a new target cell type for the immunodeficiency virus-1?** *Faseb J* 2002, **16(10)**:1254-1256.
37. Zilberfarb V, Pietri-Rouxel F, Jockers R, Krief S, Delouis C, Issad T, Strosberg AD: **Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis.** *J Cell Sci* 1997, **110(Pt 7)**:801-807.
38. Petit C, Mathez D, Barthelemy C, Leste-Lasserre T, Naviaux RK, Sonigo P, Leibowitch J: **Quantitation of Blood Lymphocyte Mitochondrial DNA for the Monitoring of Antiretroviral Drug-Induced Mitochondrial DNA Depletion.** *J Acquir Immune Defic Syndr* 2003, **33(4)**:461-469.
39. Paradis V, Bieche I, Dargere D, Bonvoust F, Ferlicot S, Olivi M, Lagha NB, Blanchet P, Benoit G, Vidaud M, et al.: **hTERT expression in sporadic renal cell carcinomas.** *J Pathol* 2001, **195(2)**:209-217.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

